The purpose of this study was to evaluate the efficacy of combined @entity3753 and @entity134 treatment for @entity1596 caused by @entity5603 in immunocompetent @entity1 . Five @entity1 (7 eyes) with @entity10629 ( @entity10629 ) were used in this study. @entity13871 was suspected based on clinical manifestations and confirmed by anti-toxocara IgG and Western blot analysis. Systemic @entity3753 (adults: 800 mg b.i.d.; @entity1 : 400 mg b.i.d.) was given in conjunction with @entity230 . Visual acuity before and after therapy, inflammatory response, side effects and @entity137 were evaluated. Treatment resulted in an improved visual acuity in all @entity1 . Mean initial Snellen visual acuity was 20/40, and mean final acuity was 20/20. There were no recurrences of @entity1596 throughout the observation period (average: 13.8 months; range: 3 days to 24 months). These findings suggest that @entity3753 , in combination with systemic @entity230 , is a useful regimen to treat @entity10629 .

Treatment of @entity13871 with XXXX .

@entity3753 :: ('MESH:D015766', 'Chemical') :: ['albendazole'] @entity1 :: ('9606', 'Species') :: ['children', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity1596 :: ('MESH:D014605', 'Disease') :: ['uveitis'] @entity5603 :: ('6265', 'Species') :: ['Toxocara canis'] @entity134 :: ('CHEBI:35341', 'Chemical') :: ['steroid'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity13871 :: ('MESH:D014120', 'Disease') :: ['Toxocariasis'] @entity10629 :: ('MESH:D007815', 'Disease') :: ['ocular larva migrans syndrome', 'OLM']
@entity3753 :: (MESH:D015766,Chemical) :: ['albendazole']
